Drug Profile
MB 11316
Alternative Names: MB11316Latest Information Update: 27 Mar 2014
Price :
$50
*
At a glance
- Originator Mazence
- Developer KT&G Life Sciences
- Class
- Mechanism of Action Nicotinamide adenine dinucleotide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Dry eyes
Most Recent Events
- 31 Oct 2013 No development reported - Phase-II for Dry eyes in South Korea (unspecified route)
- 30 Mar 2012 Mazence is now called KT&G Life Sciences